Vasoactive Intra--arterial Therapy in Peripheral Occlusive Arterial Disease (With Follow--up After 6.5 Years)

van der Molen, H. R.
April 1980
Angiology;Apr1980, Vol. 31 Issue 4, p221
Academic Journal
The article focuses on vasoactive intra-arterial therapy in peripheral occlusive arterial disease. Treatment of obliterative disease in general, but especially in claudication and trophic ulcers, has to combine five elements: (1) a complete stop of smoking; (2) a reasonable diet reducing solid fats and sugar, and changing to vegetable oils such as com oil and safflower oil, which contain unsaturated fats as well as tocopherols; (3) exercise of all kinds, including walking, biking, and swimming; (4) high doses of C and B vitamins; and (5) intra-arterial pharmacologic treatment. Quite naturally, all kinds of vasodilating drugs were tried, but their effect on the disease was not always favorable.


Related Articles

  • Reliability of treadmill testing in peripheral arterial disease: a comparison of a constant load with a graded load treadmill protocol. Labs, K-H.; Jaeger, K.A.; Nehler, M.R.; Roessner, M.; Hiatt, W.R. // Vascular Medicine;1999, Vol. 4 Issue 4, p239 

    This study aims to evaluate the reliability of repeated graded workload treadmill testing (G-test; 2 mph; 0% grade, increasing 2% every 2 min) and to compare the reliability of a constant workload treadmill protocol (C-test; 2 mph; 12% grade) versus the graded workload treadmill protocol in...

  • Effects of Supervised Treadmill Walking Training on Calf Muscle Capillarization in Patients With Intermittent Claudication. Jianxiong Wang; Shi Zhou; Bronks, Roger; Graham, John; Myers, Stephen // Angiology;Feb/Mar2009, Vol. 60 Issue 1, p36 

    The aim of this study was to evaluate the effects of supervised treadmill walking training on the calf muscle capillarization in patients with intermittent claudication. The first 12-week period was a nonexercise, within-subject control stage, and the second 12-week period was an exercise...

  • Exercise Rehabilitation for the Patient with Intermittent Claudication: A highly Effective yet Underutilized Treatment. Regensteiner, Judith G. // Current Drug Targets - Cardiovascular & Haematological Disorders;Sep2004, Vol. 4 Issue 3, p233 

    Peripheral arterial disease (PAD), when accompanied by claudication, is a disabling disease that affects 12 percent of the population of the United States (US). PAD is associated with increased mortality as well as decreased functional status and quality of life. Smoking cessation and treatment...

  • Physical Performance in Peripheral Arterial Disease: A Slower Rate of Decline in Patients Who Walk More. McDermott, Mary McGrae; Kiang Liu; Ferrucci, Luigi; Criqui, Michael H.; Greenland, Philip; Guralnik, Jack M.; Lu Tian; Schneider, Joseph R.; Pearce, William H.; Jin Tan; Martin, Gary J. // Annals of Internal Medicine;1/3/2006, Vol. 144 Issue 1, p10 

    Background: Exercise rehabilitation programs increase treadmill walking performance in patients with peripheral arterial disease (PAD) and intermittent claudication. However, it is unknown whether patients with PAD who walk for exercise regularly have less functional decline than those with less...

  • The New England Journal of Drugs. Gaby, Alan R. // Townsend Letter for Doctors & Patients;Aug/Sep2003, Issue 241/242, p152 

    Editorial. Comments on the article discussing the treatment of intermittent claudication published in the periodical 'New England Journal of Medicine.' Failure of vitamin E to affect intermittent claudification; Basis on the assertion of the author regarding vitamin E; Bias of the periodical...

  • Pharmacotherapy for Peripheral Arterial Disease: Emerging Therapeutic Options. Jaff, Michael R. // Angiology;Nov/Dec2002, Vol. 53 Issue 6, p627 

    Although endovascular therapy has revolutionized the management of patients with peripheral arterial disease (PAD), noninterventional regimens, such as structured exercise therapy, atherosclerotic risk factor modification, and pharmacotherapy, are effective in patients suffering from...

  • Cilostazol: A Viewpoint by David Dawson. Dawson, D. // Drugs & Aging;1999, Vol. 14 Issue 1, p72 

    Focuses on the uses of cilostazol for the treatment of intermittent claudication in patients with peripheral artery disease (PAD). Recognizable symptom of PAD; Nature and implication of claudication symptoms; Efficacy and use of cilostazol.

  • TREATMENT OF INTERMITTENT CLAUDICATION. Boyd, A. M.; Marks, J. // Angiology;Apr1963, Vol. 14 Issue 4, p198 

    A blind controlled trial was carried out to study the effect of α-tocopherol in a group of patients with intermittent claudication. After a trial period lasting 13 weeks, the effect of treatment was assessed by (1) the walking distance before the onset of pain and (2) the total walking...

  • Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication. Mohler III, E.R.; Beebe, H.G.; Salles-Cuhna, S.; Zimet, R.; Zhang, P.; Heckman, J.; Forbes, W.P. // Vascular Medicine;2001, Vol. 6 Issue 3, p151 

    During exercise, patients with intermittent claudication (IC) have decreased limb arterial blood pressure that recovers during rest. A novel method for assessing dynamic recovery of function is measurement of the hemodynamic response after exercise. Cilostazol (Pletal®), a new agent for the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics